
|Videos|July 15, 2014
Treatment Options for Multicentric Castleman's Disease
Author(s)Frits van Rhee, MD, PhD, MRCP
Frits van Rhee, MD, PhD, MRCP, professor of medicine, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, discusses treatment options for multicentric Castleman's disease.
Advertisement
Siltuximab is now approved for multicentric Castleman’s disease > >
Clinical Pearls
Frits van Rhee, MD, PhD, MRCP, professor of medicine, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, discusses treatment options for multicentric Castleman's disease.
- Multicentric Castleman's disease is a benign lymph node disorder in which patients get sick and notice lumps and bumps.
- There is currently no standard of care for this group of patients who are not infected with HIV.
- Being a rare disease, there have been no large studies conducted in this space.
- Steroids and rituximab are commonly used to treat this disease.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5








































